Joint Pain: What Could Be Causing It?

Why Joint Pain Has So Many Possible Causes

A joint is where two bones meet, surrounded by cartilage, synovial membrane, ligaments, tendons, bursae, and fluid. Damage or inflammation at any of these structures produces pain. That anatomical complexity explains why the differential diagnosis for arthralgia runs so long, spanning mechanical wear, immune-mediated destruction, crystal deposition, infection, and referred pain from extra-articular sources.

The 2019 Global Burden of Disease study estimated that osteoarthritis alone affected 528 million people worldwide, a 113% increase since 1990 [1]. Yet osteoarthritis is only one entry on a list that includes more than 100 conditions capable of causing joint symptoms. Separating them requires a systematic approach built on four clinical pillars: the number of joints involved (mono-, oligo-, or polyarticular), whether the pattern is symmetric or asymmetric, whether inflammation is present (swelling, warmth, morning stiffness lasting longer than 30 minutes), and the time course (acute versus chronic).

The American College of Rheumatology (ACR) recommends that clinicians first classify joint pain by inflammatory versus non-inflammatory features before ordering labs [2]. A swollen, warm, erythematous joint suggests synovitis or crystal disease. A painful joint that worsens with activity but lacks swelling more often points toward osteoarthritis or periarticular pathology like tendinopathy. This distinction alone cuts the diagnostic possibilities roughly in half.

Osteoarthritis: The Most Common Culprit

Osteoarthritis (OA) is the leading cause of chronic joint pain in adults over 50. It results from progressive cartilage breakdown, subchondral bone remodeling, and low-grade synovial inflammation. The joints most frequently affected are the knees, hips, hands (especially the DIP joints), and spine.

CDC data from the 2024 Vital Signs report show that 32.8 million U.S. adults carry an OA diagnosis, with prevalence rising sharply after age 45 [3]. Risk factors include age, obesity, prior joint injury, female sex, and repetitive occupational loading. Knee OA prevalence has doubled since the mid-20th century, even after adjusting for age and BMI, suggesting that modern sedentary lifestyles and other environmental factors play a role [4].

Diagnosis is clinical. The ACR criteria for knee OA require knee pain plus at least three of: age over 50, morning stiffness lasting fewer than 30 minutes, crepitus, bony tenderness, bony enlargement, and no palpable warmth [2]. X-rays may show joint space narrowing, osteophytes, and subchondral sclerosis, but radiographic severity correlates poorly with symptom burden. An MRI is rarely needed unless the presentation is atypical.

First-line treatment combines weight management, structured exercise (particularly quadriceps strengthening for knee OA), and topical NSAIDs. Oral NSAIDs at the lowest effective dose remain a mainstay, though the 2019 ACR/Arthritis Foundation guidelines conditionally recommend against chronic opioid use for OA [5]. Intra-articular corticosteroid injections provide short-term relief; hyaluronic acid injections show modest benefit in some patients, though guideline support varies. Joint replacement is reserved for refractory disease.

Rheumatoid Arthritis and Other Autoimmune Causes

Rheumatoid arthritis (RA) affects approximately 1.3 million Americans and is the prototypical inflammatory polyarthritis [6]. It typically presents as symmetric swelling and tenderness in the MCP and PIP joints of the hands, wrists, and forefeet, with morning stiffness exceeding 60 minutes. Left untreated, RA erodes cartilage and bone within two years in most patients.

The 2010 ACR/EULAR classification criteria use a scoring system based on joint involvement, serology (RF and anti-CCP antibodies), acute-phase reactants (CRP and ESR), and symptom duration [7]. Anti-CCP antibodies are roughly 95% specific for RA and can appear years before clinical onset. Dr. Josef Smolen, lead author of the 2023 EULAR RA management recommendations, has stated: "The treat-to-target principle remains the cornerstone of RA management. Remission or low disease activity should be the goal for every patient within six months of diagnosis" [8].

Treatment follows a step-up approach. Methotrexate is the anchor drug, initiated at 10 to 15 mg weekly and titrated to 25 mg. If the target is not met by three to six months, biologic DMARDs (TNF inhibitors, IL-6 receptor blockers, or JAK inhibitors) are added. The ORAL Surveillance trial (N=4,362) showed that tofacitinib carried higher rates of major adverse cardiovascular events and malignancies compared to TNF inhibitors in patients aged 50 and older with at least one cardiovascular risk factor, prompting an FDA boxed warning on all JAK inhibitors [9].

Other autoimmune causes of joint pain include:

Psoriatic arthritis (PsA). Affects up to 30% of psoriasis patients. The pattern is typically asymmetric oligoarthritis with dactylitis ("sausage digits") and enthesitis. Axial involvement occurs in roughly 40% of cases.

Systemic lupus erythematosus (SLE). Joint pain occurs in over 90% of lupus patients, often as a non-erosive, migratory polyarthritis. ANA testing is the initial screen; anti-dsDNA and anti-Smith antibodies increase specificity.

Ankylosing spondylitis. Presents with inflammatory back pain and sacroiliitis in young adults (onset before age 45), often with peripheral joint involvement. HLA-B27 positivity supports the diagnosis.

Gout and Crystal Arthropathies

Gout is the most common inflammatory arthritis in men and the most common cause of acute monoarthritis in adults over 40 [10]. It results from monosodium urate crystal deposition in joints and periarticular tissues when serum uric acid exceeds the saturation threshold of approximately 6.8 mg/dL.

The classic presentation is sudden, excruciating pain in the first metatarsophalangeal joint (podagra), peaking within 12 to 24 hours, with overlying erythema so intense it can mimic cellulitis. The 2020 ACR guidelines for gout management recommend a treat-to-target urate-lowering strategy, aiming for serum urate below 6 mg/dL [11]. Allopurinol, started at 100 mg daily and titrated by 100 mg increments every two to five weeks, is first-line. Febuxostat is an alternative, though the CARES trial (N=6,190) found a higher rate of cardiovascular death with febuxostat compared to allopurinol, leading to an FDA safety communication [12].

Calcium pyrophosphate deposition disease (CPPD, or pseudogout) mimics gout clinically but targets different joints, most often the knee and wrist. It is diagnosed by the presence of positively birefringent, rhomboid-shaped crystals on polarized microscopy of synovial fluid, combined with chondrocalcinosis on X-ray. CPPD is strongly associated with aging, hyperparathyroidism, hemochromatosis, and hypomagnesemia. No urate-lowering equivalent exists; management relies on colchicine, NSAIDs, and corticosteroid injections for flares.

Septic Arthritis: The Emergency You Cannot Miss

Septic arthritis is a medical emergency. Bacterial infection within the joint space destroys cartilage within hours if untreated. The mortality rate for septic arthritis remains 7% to 15% even with appropriate therapy, and it rises above 30% in patients with polyarticular infection or delayed diagnosis [13].

Staphylococcus aureus causes roughly 50% to 70% of non-gonococcal septic arthritis in adults [13]. Risk factors include pre-existing joint disease (especially RA), prosthetic joints, immunosuppression, intravenous drug use, diabetes, and skin breakdown. Gonococcal arthritis should be considered in sexually active adults under 40 presenting with migratory polyarthralgia, tenosynovitis, and skin lesions.

Any acutely swollen, warm joint requires arthrocentesis before antibiotics are started. The ACR and the Infectious Diseases Society of America both emphasize that synovial fluid analysis with cell count, Gram stain, culture, and crystal examination is the single most important diagnostic step for acute monoarthritis [2]. A white blood cell count exceeding 50,000 cells/mm³ with more than 90% neutrophils is highly suggestive of infection, though crystal disease can produce counts in the same range.

Dr. Eric Matteson, former president of the ACR, has noted: "The penalty for missing septic arthritis is joint destruction, bacteremia, and potentially death. When in doubt, tap the joint" [14].

Drug-Induced Joint Pain

Medications are an underappreciated cause of arthralgia. The most common offenders include:

Aromatase inhibitors. Anastrozole, letrozole, and exemestane cause arthralgia in 35% to 50% of breast cancer patients on adjuvant therapy [15]. The ATAC trial (N=6,241) reported that musculoskeletal complaints were the leading reason for early discontinuation of anastrozole. Symptoms typically begin within two to three months of starting therapy and may improve with switching agents or adding low-dose duloxetine.

Statins. Myalgia is reported in 5% to 10% of statin users, but true arthralgia also occurs and is sometimes overlooked as coincidental OA. Statin-associated muscle symptoms (SAMS) resolve within two to four weeks of discontinuation in most cases.

Fluoroquinolones. Ciprofloxacin, levofloxacin, and moxifloxacin carry an FDA boxed warning for tendinitis and tendon rupture, but they also cause arthralgia, particularly in older adults and those on concurrent corticosteroids [16]. The mechanism involves direct toxicity to chondrocytes and tenocytes.

Checkpoint inhibitors. Immune-related arthritis occurs in 5% to 10% of patients on PD-1/PD-L1 inhibitors and can mimic RA or PsA. It may persist long after the drug is stopped.

DPP-4 inhibitors. Post-marketing reports have linked sitagliptin and saxagliptin to severe, disabling arthralgia, prompting an FDA safety communication in 2015 [17]. Symptoms resolve after drug discontinuation.

A thorough medication review is part of every joint pain workup. The temporal relationship between drug initiation and symptom onset is the strongest diagnostic clue.

The Diagnostic Workup: Labs, Imaging, and Synovial Fluid

The evaluation of joint pain follows a structured pathway that begins with history and physical examination, then layers on targeted investigations.

Blood tests. Initial labs for inflammatory joint pain should include CRP, ESR, CBC, and a metabolic panel. If RA is suspected, order RF and anti-CCP. For lupus, start with ANA. For gout, measure serum uric acid (keeping in mind that levels can be paradoxically low during acute flares). HLA-B27 is useful when ankylosing spondylitis is considered but has limited sensitivity (present in only 90% of AS patients and 6% to 8% of the general Caucasian population) [18].

Imaging. Plain radiographs remain the first-line imaging study. They detect joint space narrowing, erosions, chondrocalcinosis, and periarticular calcifications. Musculoskeletal ultrasound has emerged as a valuable bedside tool for detecting synovitis, effusions, and tophi; it is more sensitive than clinical examination for subclinical synovitis in RA [19]. MRI provides the highest soft-tissue contrast and is the gold standard for detecting early erosions, bone marrow edema, and ligamentous or meniscal pathology.

Synovial fluid analysis. This is the single most informative test for acute monoarthritis. Fluid is classified as non-inflammatory (WBC <2,000/mm³, as in OA), inflammatory (WBC 2,000 to 50,000/mm³, as in RA or crystal disease), or septic (WBC typically above 50,000/mm³). Polarized light microscopy identifies monosodium urate crystals (negatively birefringent needles in gout) or calcium pyrophosphate crystals (positively birefringent rhomboids in pseudogout). Gram stain and culture are mandatory when infection is possible.

Viral and Reactive Arthritis

Viral infections are a common but often overlooked cause of self-limited polyarthralgia, especially in younger adults.

Parvovirus B19. Causes a symmetric polyarthritis mimicking RA, primarily in women. Joint symptoms appear as viremia clears and IgM antibodies rise. The condition is self-limited, typically resolving within two to four weeks, though some patients experience months of intermittent symptoms [20].

Hepatitis B and C. HBV-associated polyarthritis occurs during the prodromal phase of acute infection and is immune-complex mediated. Chronic HCV infection is associated with mixed cryoglobulinemia, which can cause arthralgias and palpable purpura.

Chikungunya and other arboviruses. Chikungunya causes severe polyarthralgia in over 90% of infected individuals, and chronic joint symptoms persist beyond three months in 40% to 60% of cases [21]. With expanding geographic range due to Aedes mosquito migration, this diagnosis is increasingly relevant in temperate regions.

Reactive arthritis. This sterile, post-infectious inflammatory arthritis occurs one to four weeks after genitourinary (Chlamydia trachomatis) or gastrointestinal (Salmonella, Shigella, Campylobacter, Yersinia) infections. The classic triad of arthritis, urethritis, and conjunctivitis is present in fewer than one-third of cases [22]. Most episodes resolve within three to six months, but 15% to 20% of patients develop chronic arthritis.

Less Common but Clinically Important Causes

Hemochromatosis. Hereditary iron overload produces a distinctive arthropathy affecting the second and third MCP joints. The hand X-ray shows hook-like osteophytes and chondrocalcinosis. Transferrin saturation above 45% and elevated ferritin prompt HFE gene testing.

Hypothyroidism. Joint stiffness and myalgia occur in up to 30% of hypothyroid patients. Symptoms resolve with adequate levothyroxine replacement. TSH should be checked in any patient with unexplained diffuse arthralgia and fatigue.

Sarcoidosis. Acute sarcoid arthritis (Löfgren syndrome) presents with bilateral ankle arthritis, erythema nodosum, and bilateral hilar lymphadenopathy. It has an excellent prognosis, with over 90% of cases resolving within two years.

Fibromyalgia. Widespread pain, including periarticular pain that patients describe as "joint pain," is the hallmark. Fibromyalgia does not cause true synovitis. The 2016 revised diagnostic criteria require a widespread pain index score of 7 or higher and a symptom severity score of 5 or higher, or WPI of 4 to 6 with SSS of 9 or higher [23]. Recognizing fibromyalgia prevents unnecessary rheumatologic workups.

When to Seek Urgent Evaluation

Most joint pain is not an emergency. Some presentations are. Seek same-day evaluation for any of the following:

A single hot, swollen joint with fever. This is septic arthritis until proven otherwise. Rapid joint destruction occurs within 24 to 48 hours without IV antibiotics and drainage.

New polyarthritis with rash, oral ulcers, or unexplained weight loss. These features suggest SLE, vasculitis, or another systemic autoimmune disease that may involve organs beyond the joints.

Joint pain after a tick bite or with an expanding erythema migrans rash. Lyme arthritis, caused by Borrelia burgdorferi, typically affects the knee and responds to a 28-day course of oral doxycycline [24]. Early treatment prevents chronic Lyme arthritis.

Joint pain with morning stiffness lasting longer than 60 minutes and persisting for more than six weeks. This pattern warrants referral to rheumatology. The 2010 ACR/EULAR criteria allow RA classification with as few as six weeks of symptoms, and early DMARD initiation within the first 12 weeks of disease dramatically improves long-term outcomes [7].

Progressive joint pain in a patient on immunosuppressive therapy warrants urgent infection exclusion, as the usual inflammatory signs may be blunted by the medications themselves.